Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients

Ming Y Lim, Katarzyna JamiesonDepartment of Medicine, Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USAAbstract: Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder that affects approximately 14,000 persons each year in the US. AML occurs at all ages...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lim MY, Jamieson K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	AML elderly management sapacitabine Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/aed040d05b6540809c2b6a817728bb87
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aed040d05b6540809c2b6a817728bb87
record_format	dspace
spelling	oai:doaj.org-article:aed040d05b6540809c2b6a817728bb872021-12-02T03:43:51ZProfile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients1178-1998https://doaj.org/article/aed040d05b6540809c2b6a817728bb872014-05-01T00:00:00Zhttps://www.dovepress.com/profile-of-sapacitabine-potential-for-the-treatment-of-newly-diagnosed-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Ming Y Lim, Katarzyna JamiesonDepartment of Medicine, Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USAAbstract: Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder that affects approximately 14,000 persons each year in the US. AML occurs at all ages but the incidence increases with age with the median age at diagnosis being 67 years. Advances in the treatment of AML over the past decades have led to improved survival, albeit mostly in younger patients. The prognosis of older patients with this disease over the same time span has not changed much and remains dismal. This review focuses on the epidemiology and characteristics of AML in elderly patients, the rationale for treating elderly AML patients, and the currently available and potential future treatment options such as sapacitabine. Elderly AML patients treated with intensive chemotherapy have a higher mortality rate, and a lower rate of complete remission and overall survival when compared to the younger population. This is due to both the different biology of the disease and the number of patient-specific factors. However, elderly AML patients treated with aggressive chemotherapy can achieve durable remissions, which offer prolonged survival and improved quality of life. Recent data also indicates that elderly AML patients deemed unfit for intensive chemotherapy benefit from leukemia-specific attenuated dose chemotherapy compared to supportive care alone. This has led to renewed interest to look for anti-leukemic therapies designed specifically for older patients. Sapacitabine, a novel oral nucleoside analog, promises good efficacy, favorable toxicity profile, and ease of administration; all of which makes it very appealing. Results from pre-clinical and clinical studies have been very encouraging and sapacitabine is currently being evaluated in a Phase III study, of which the results are eagerly awaited.Keywords: AML, elderly, management, sapacitabineLim MYJamieson KDove Medical PressarticleAMLelderlymanagementsapacitabineGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 9, Pp 753-762 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	AML elderly management sapacitabine Geriatrics RC952-954.6
spellingShingle	AML elderly management sapacitabine Geriatrics RC952-954.6 Lim MY Jamieson K Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
description	Ming Y Lim, Katarzyna JamiesonDepartment of Medicine, Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USAAbstract: Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder that affects approximately 14,000 persons each year in the US. AML occurs at all ages but the incidence increases with age with the median age at diagnosis being 67 years. Advances in the treatment of AML over the past decades have led to improved survival, albeit mostly in younger patients. The prognosis of older patients with this disease over the same time span has not changed much and remains dismal. This review focuses on the epidemiology and characteristics of AML in elderly patients, the rationale for treating elderly AML patients, and the currently available and potential future treatment options such as sapacitabine. Elderly AML patients treated with intensive chemotherapy have a higher mortality rate, and a lower rate of complete remission and overall survival when compared to the younger population. This is due to both the different biology of the disease and the number of patient-specific factors. However, elderly AML patients treated with aggressive chemotherapy can achieve durable remissions, which offer prolonged survival and improved quality of life. Recent data also indicates that elderly AML patients deemed unfit for intensive chemotherapy benefit from leukemia-specific attenuated dose chemotherapy compared to supportive care alone. This has led to renewed interest to look for anti-leukemic therapies designed specifically for older patients. Sapacitabine, a novel oral nucleoside analog, promises good efficacy, favorable toxicity profile, and ease of administration; all of which makes it very appealing. Results from pre-clinical and clinical studies have been very encouraging and sapacitabine is currently being evaluated in a Phase III study, of which the results are eagerly awaited.Keywords: AML, elderly, management, sapacitabine
format	article
author	Lim MY Jamieson K
author_facet	Lim MY Jamieson K
author_sort	Lim MY
title	Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
title_short	Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
title_full	Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
title_fullStr	Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
title_full_unstemmed	Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
title_sort	profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/aed040d05b6540809c2b6a817728bb87
work_keys_str_mv	AT limmy profileofsapacitabinepotentialforthetreatmentofnewlydiagnosedacutemyeloidleukemiainelderlypatients AT jamiesonk profileofsapacitabinepotentialforthetreatmentofnewlydiagnosedacutemyeloidleukemiainelderlypatients
_version_	1718401691925086208

Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients

Ejemplares similares